Astellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell Therapy

Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. announced Friday the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.

RTTNews | 242 days ago

Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen Inc. (SGEN) and Astellas Pharma Inc. (ALPMY.PK, ALPMY).

RTTNews | 424 days ago

Canadian Market Recovers Well After Early Setback

The Canadian market, which slid in early trades Tuesday morning on hot inflation data, and rising geopolitical concerns following an escalation in Russia - Ukraine war, recovered lost ground subsequently with a few frontline stocks finding some solid support at lower levels.

RTTNews | 5h 28min ago

U.S. Housing Starts Tumble 3.1% In October, More Than Expected

New residential construction in the U.S. tumbled by more than expected in the month of October, according to a report released by the Commerce Department on Tuesday. The report said housing starts dove by 3.1 percent to an annual rate of 1.311 million in October after slumping by 1.9 percent to a revised rate of 1.353 million in September.

RTTNews | 8h 3min ago

U.S. Housing Starts Tumble More Than Expected In October

New residential construction in the U.S. tumbled by more than expected in the month of October, according to a report released by the Commerce Department on Tuesday.

RTTNews | 9h 2min ago

Eurozone Inflation Rises To 2% As Estimated

Eurozone inflation returned to the 2 percent target in October, final data from Eurostat showed on Tuesday. The harmonized index of consumer prices climbed as initially estimated in October after rising 1.7 percent in September. Core inflation that excludes prices of energy, food, alcohol and tobacco, remained unchanged at 2.7 percent in October.

RTTNews | 9h 21min ago

Bay Street Seen Opening Lower On Geopolitical Concerns; Canadian Inflation Data In Focus

Canadian shares look headed for a weak start on Tuesday amid rising geopolitical concerns after Russian President Vladimir Putin updated nuclear doctrine.

RTTNews | 9h 46min ago

Euro Slides Against Majors

The euro weakened against other major currencies in the European session on Tuesday, as traders are worried that protectionist policies by President-elected Donald Trump could disrupt the Eurozone's growth potential.

RTTNews | 9h 51min ago

EURUSD	1.05809	GBPUSD	1.26744	AUDUSD	0.65239
USDJPY	154.592	USDCAD	1.39749	USDCHF	0.88262